DFO
RARE icon

Duquesne Family Office’s Ultragenyx Pharmaceutical RARE Stock Holding History

Duquesne Family Office’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-85,445
Closed -$3.09M – 81
2025
Q1 		$3.09M Hold
85,445
– – 0.1% 49
2024
Q4 		$3.6M Hold
85,445
– – 0.1% 74
2024
Q3 		$4.75M Buy
+85,445
New +$4.35M 0.16% 66

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Duquesne Family Office's RARE Position: Q2 2025 in Review

Duquesne Family Office sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2025, closing a stake of 85,445 shares — an estimated $3.09M sold.

Duquesne Family Office first reported a position in RARE in Q3 2024 and held it in 3 quarters. The position peaked at $4.75M in Q3 2024. 309 funds tracked by Wall St. Rank hold RARE as of Q2 2025.

  • Duquesne Family Office reported no remaining Ultragenyx Pharmaceutical position as of Q2 2025 after selling out during the quarter.
  • Duquesne Family Office sold 85,445 Ultragenyx Pharmaceutical shares in Q2 2025, an estimated $3.09M.
  • Duquesne Family Office first reported a position in Ultragenyx Pharmaceutical in Q3 2024 and held it in 3 quarters.
  • Duquesne Family Office's Ultragenyx Pharmaceutical position peaked at $4.75M in Q3 2024.
  • 309 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2025.

Based on Duquesne Family Office's 13F filing for Q2 2025, filed 15 Aug 2025.